CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Revenues:
License and milestone fees	$ 39,455	$ 24,227	$ 9,161
Royalty revenue	10,346	592
Research and development support	7,187	7,873	4,517
Clinical materials revenue	2,908	2,843	2,679
Total revenues	59,896	35,535	16,357
Operating Expenses:
Research and development	106,958	87,073	69,192
General and administrative	24,469	21,471	20,422
Total operating expenses	131,427	108,544	89,614
Loss from operations	(71,531)	(73,009)	(73,257)
Investment income, net	44	126	66
Other income (expense), net	123	72	(128)
Net loss	(71,364)	(72,811)	(73,319)
Basic and diluted net loss per common share (in dollars per share)	$ (0.83)	$ (0.87)	$ (0.95)
Basic and diluted weighted average common shares outstanding (in shares)	85,481	84,063	76,814
Total Comprehensive Loss	$ (71,364)	$ (72,811)	$ (73,319)